Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyNeuro-OncologyDiseaseBile Duct CarcinomaOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationICD10C24.-C24.0C24.1C24.8C24.9C25.-C56MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceChemotherapyChemo-substanceDabrafenibTrametinibChemo-substanceDabrafenibTrametinibChemo-substanceDabrafenibTrametinibChemo-substanceDabrafenibTrametinibNo. Substances2 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicity (ASCO)Febrile NeutropeniaHeadacheHyponatremiaIncrease Alkaline PhosphataseIncrease AminotransferasesNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorSalama AKSDiseaseLokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2OriginDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HProtocols in Revision 1 protocol foundProtocols under revision.Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)
